<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322020</url>
  </required_header>
  <id_info>
    <org_study_id>S2016-0351-0001</org_study_id>
    <nct_id>NCT03322020</nct_id>
  </id_info>
  <brief_title>Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer</brief_title>
  <acronym>ADEBAR</acronym>
  <official_title>Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Men With Intermediate- or High-risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the treatment for intermediate- and high-risk prostate cancer, Cyberknife boost will be
      used after 4 weeks of intensity modulated radiotherapy to pelvis. The boost doses are 18 Gy
      and 21 Gy in 3 fractions, respectively. The investigators plan to evaluate the toxicity of
      two dose groups and decide the appropriate dose for Cyberknife boost. Also, PSA control will
      be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2016</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity assessment for 18 Gy and 21 Gy arm</measure>
    <time_frame>3 months</time_frame>
    <description>CTCAE v4.03, overactive bladder symptom score (OABSS), International Prostate Symptom Score (IPSS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical control free survival</measure>
    <time_frame>3 years</time_frame>
    <description>PSA nadir + 2.0ng/ml or Start of salvage hormonal therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity assessment for 18 Gy and 21 Gy arm</measure>
    <time_frame>average 6 months</time_frame>
    <description>Late Effects of Normal Tissues (LENT) scoring system</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neoplasm, Prostate</condition>
  <arm_group>
    <arm_group_label>CK 18 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who receive Cyberknife boost dose of 18 Gy in 3 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CK 21 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who receive Cyberknife boost dose of 21 Gy in 3 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cyberknife boost 18 Gy</intervention_name>
    <description>pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx</description>
    <arm_group_label>CK 18 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cyberknife boost 21 Gy</intervention_name>
    <description>pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx</description>
    <arm_group_label>CK 21 Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed intermediate- or high-risk prostate cancer within 6 months
             after enrollment

          -  ECOG performance status 0-1

          -  Appropriate values of blood tests within 6 months after enrollment Absolute neutrophil
             count (ANC) ≥ 1500 cells/mm3 Platelets ≥ 50,000 cells/mm3 Hemoglobin ≥ 8.0 g/dl

          -  Appropriate values of kidney function within 6 months after enrollment Creatinine &lt;
             2.0 ng/dL

          -  Appropriate values of liver function within 6 months after enrollment total bilirubin
             &lt; 1.5 X maximum normal value alanine aminotransferase or aspartate aminotransferase &lt;
             2.5 X maximum normal value

        Exclusion Criteria:

          -  Presence of distant metastasis

          -  Presence of pelvic LN metastasis

          -  History of androgen deprivation therapy within 6 months after enrollment

          -  History of definitive treatment for prostate cancer (e.g., radical prostatectomy)

          -  History of pelvic irradiation

          -  Double primary cancer other than skin/thyroid cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Seok Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young Seok Kim, M.D., Ph.D.</last_name>
    <phone>+82 2 3010 5614</phone>
    <email>ysk@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Seok Kim, M.D., Ph.D.</last_name>
      <phone>+82 2 3010 5614</phone>
      <email>ysk@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Yeon Joo Kim, M.D.</last_name>
      <phone>+82 2 3010 0064</phone>
      <email>kamea1004@naver.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young Seok Kim</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

